ROS1 and non-small cell lung carcinoma: Previously, the ROS1 inhibitor crizotinib showed a high response rate (objective response rate [ORR] of 72%; median duration of response: 17.6 months, n = 50) [17], and it is approved globally for use in advanced NSCLC patients with ROS1 fusions.